TILs RNA silencing guide

TIL therapy faces unique manufacturing, biological, and clinical barriers that limit broader application:

Extreme T cell exhaustion at baseline

TILs emerge from chronic tumor antigen exposure in immunosuppressive microenvironments, resulting in one of the most exhausted T cell phenotypes known: high percentages of TILs express PD-1 (significantly higher than peripheral blood T cells or CAR-T after expansion), many co-express TIM-3, LAG-3, and CD39, and often show high TOX and NR4A1 nuclear accumulation (exhaustion transcription factors). This exhaustion phenotype can limit proliferative capacity during REP (some patient TILs fail to expand adequately, with manufacturing failure rates reported in the literature), may reduce cytokine production (IFN-γ, TNF-α, IL-2) critical for tumor killing, and can shorten in vivo persistence post-infusion (rapid re-exhaustion in tumor microenvironment).

REP manufacturing complexity and failure risk

The Rapid Expansion Protocol requires 14-28 days of culture with anti-CD3 (OKT3) stimulation, high-dose IL-2 (3000-6000 U/mL), and irradiated allogeneic feeder PBMCs (typically 100-200 fold excess over TILs). This complex system achieves 1000-10,000 fold expansion but suffers from: complete manufacturing failures reported in the literature (inadequate expansion, contamination, or loss of tumor reactivity), extensive phenotypic skewing (depletion of memory TILs, accumulation of terminally differentiated effectors with poor persistence), variable REP performance across tumor types (melanoma best, others more challenging), and high cost (GMP feeder cells, extensive quality control, 6-8 week vein-to-vein timeline).

Transfection-induced toxicity in fragile TILs

TILs are exceptionally fragile compared to healthy peripheral blood T cells. They have already experienced chronic activation, metabolic stress, and apoptotic pressure in tumors. Introducing genetic modifications via electroporation causes significant immediate cell death (substantially higher than in peripheral T cells or CAR-T). Surviving TILs show further exhaustion marker upregulation, reduced REP expansion potential, and altered memory phenotype distribution. That cost is hard for a TIL batch to carry, because TIL manufacturing already faces baseline failure rates reported in the literature. Adding electroporation further reduces yield and creates cells with compromised therapeutic potential.

Regulatory T cell contamination

Tumor tissue contains CD4+FOXP3+ regulatory T cells (Tregs) that suppress anti-tumor immune responses. During TIL isolation and expansion, Tregs can comprise 10-40% of the final product (varies by tumor type (higher in ovarian, pancreatic cancers). These contaminating Tregs actively suppress effector TIL function through IL-10, TGF-β secretion, and direct cell contact inhibition (CTLA-4 engagement). Manufacturing protocols attempt Treg depletion (CD25 bead depletion, selective expansion favoring effectors), but Tregs persist and reduce therapeutic efficacy. Genetic approaches to disable the Treg program (FOXP3 knockdown) by conventional transfection can cost more of the fragile TILs beside them than a batch can spare.

Loss of neoantigen-specific TIL clones during REP

Pre-REP TIL populations contain rare tumor-reactive clones recognizing patient-specific neoantigens (mutated self-proteins unique to tumor). During the aggressive REP expansion, these high-value clones may be outcompeted by non-reactive bystander T cells or clones recognizing irrelevant antigens, resulting in dilution of tumor reactivity. Enrichment strategies (activation-induced marker sorting for 4-1BB+, CD137+, or OX40+ TILs after tumor peptide stimulation) can identify reactive clones, but adding enhancement after enrichment requires transfection-free methods.

Tumor microenvironment re-exhaustion post-infusion

Even successfully manufactured TILs re-encounter the same immunosuppressive tumor microenvironment that exhausted them initially: high TGF-β (suppresses T cell activation), adenosine (via ADORA2A receptor inhibits cytotoxicity), IL-10 (immunosuppressive), low nutrients (glucose, glutamine), and hypoxia. Without resistance mechanisms, infused TILs rapidly re-exhaust: upregulate PD-1, TIM-3, LAG-3 within days to weeks, lose cytotoxic function, and fail to persist. Clinical combination with checkpoint inhibitor antibodies (anti-PD-1) addresses this partially but requires systemic antibody dosing with associated toxicities.

Method comparison

Gene silencing in TILs with no transfection reagent

Enhancement without transfection toxicity

Key benefits

• Silences the drivers of exhaustion. TOX is the master exhaustion transcription factor and NR4A1 an exhaustion mediator, and the checkpoint receptors (PD-1, LAG-3, TIM-3) carry the signal. Read exhaustion marker co-expression, proliferation during REP, IFN-γ production, tumor killing and the CD62L+ central memory fraction against the untreated arm.
• Silences the FAS pathway before REP. FAS and FASLG carry activation-induced cell death, and TOX drives the exhaustion program, so REP fold-expansion is the readout to take against the untreated arm of the same patient batch. That comparison is what a batch near the failure threshold turns on, and the challenging batches are the non-melanoma solid tumors and the TILs of patients treated with a checkpoint inhibitor, where the literature reports the failures.
• Adds knockdown after neoantigen sorting. Combine with activation marker sorting (4-1BB+ enrichment after tumor stimulation). Sorted neoantigen-specific TILs are highly exhausted, and no cationic lipid or pulse is applied to a population this small. Read tumor reactivity of the sorted and treated cells against the sorted cells alone.
• Silences FOXP3 in contaminating Tregs. CD4+FOXP3+ Tregs are 10-40% of a TIL product, and FOXP3 is the transcription factor their suppressive program depends on. Electroporation-based Treg depletion carries the cost to the batch named in the challenges above; AUMsilence sdASO is added to the medium instead. Read effector TIL proliferation and cytokine production against the untreated arm.
• Confers tumor microenvironment resistance. Knockdown of TGFβR2, IL-10R, or ADORA2A makes TILs less responsive to TGFβ, IL-10 or adenosine in culture, read out as proliferation and cytokine production in a suppression assay beside the untreated control.
• Fits an existing protocol. Added to the medium of an existing TIL expansion protocol. No new equipment, no protocol changes and no training. Can be implemented in any laboratory expanding TILs, with minimal infrastructure investment.

Cell types and applications

• TIL expansion protocol optimization (pre-REP, REP, post-REP enhancement)
• Exhaustion reversal (TOX, NR4A1, checkpoint receptor knockdown)
• REP expansion enhancement (prevent activation-induced cell death)
• Neoantigen-specific TIL enrichment and enhancement (4-1BB+ sorted TILs)
• Treg depletion (FOXP3 knockdown)
• Tumor microenvironment resistance (TGFβR2, IL-10R, ADORA2A silencing)
• Combination with checkpoint inhibitor antibodies (genetic + antibody blockade)
• TIL persistence improvement (metabolic reprogramming, anti-apoptotic strategies)
• Quality control biomarker discovery (identify exhaustion/persistence predictors)
• Translational TIL research (mechanism discovery, target validation)
• Non-melanoma TIL research (lung, cervical, ovarian, head/neck cancers)
• Prior checkpoint inhibitor failure populations (restore TIL function)

Alternative products

• AUMsilence™ sdASO™
• AUMsilence™ toASO™
• Custom ASO design service

Optimized protocols for integrating gene silencing into TIL expansion workflows at pre-REP, REP, and post-REP stages. No transfection reagent and no equipment are required.

Quick start protocol (all TIL applications)

1. 01Isolate TILs from tumor digest (enzymatic digestion: collagenase IV + DNase, 37°C, 1-2h)
2. 02Culture in complete medium (RPMI + 10% human serum + IL-2 6000 U/mL) at 1 × 10⁶ cells/mL
3. 03At Day 2-3 of pre-REP, add AUMsilence™ sdASO™ directly to culture at 10 μM (no transfection reagent)
4. 04Continue pre-REP expansion (7-14 days total). Re-dose ASO after 3 to 5 days if sustained knockdown desired.
5. 05Validate knockdown by qRT-PCR (48-72h) and flow cytometry (72-96h); read tumor reactivity against the untreated arm
6. 06Proceed to REP according to the standard TIL expansion protocol

Cell-type-specific protocols

Silence exhaustion markers during initial TIL expansion before REP

1. 01

   Step 1: TIL isolation from tumor tissue

   Receive fresh tumor specimen (1-2 cm³ minimum from surgical resection). Mechanically fragment tumor into 2-3 mm pieces. Enzymatic digestion: collagenase IV (1 mg/mL) + DNase I (0.02 mg/mL) in RPMI, 37°C, 1-2h with gentle agitation. Pass through 70 μm cell strainer. Wash 2× with RPMI. Resuspend in complete TIL medium: RPMI-1640 + 10% heat-inactivated human AB serum + 1% Pen/Strep + recombinant human IL-2 (6000 U/mL, aldesleukin).
   Materials: Tumor tissue, collagenase IV, DNase I, RPMI, human AB serum, IL-2 (6000 U/mL)
   Note: Yield varies: melanoma 10⁷-10⁸ TILs per gram tumor, other solid tumors may yield less. TILs are heterogeneous: CD8+ cytotoxic, CD4+ helper, CD4+FOXP3+ Tregs (10-40%).
   Timing: Day 0
2. 02

   Step 2: Pre-REP initial expansion

   Seed TILs at 1-2 × 10⁶ cells/mL in complete TIL medium + IL-2 (6000 U/mL) in tissue culture flasks or gas-permeable culture devices. Culture at 37°C, 5% CO₂. Monitor cell density every 2-3 days. Split to maintain 0.5-2 × 10⁶/mL if density exceeds 3 × 10⁶/mL. Pre-REP duration: 7-14 days (goal: identify and expand initial tumor-reactive TILs).
   Materials: Complete TIL medium + IL-2 (6000 U/mL), tissue culture flasks or gas-permeable culture devices
   Note: Pre-REP is selection phase. Tumor-reactive TILs with appropriate TCR specificity expand preferentially. High IL-2 maintains survival but also drives exhaustion.
   Timing: Day 0-14
3. 03

   Step 3: AUMsilence sdASO treatment (pre-REP checkpoint knockdown)

   At Day 2-3 of pre-REP (after TILs recover from isolation stress), add AUMsilence sdASO targeting PD-1 (PDCD1), LAG-3, or TIM-3 (HAVCR2) at 10 μM directly to culture. For example: PD-1 knockdown creates checkpoint-resistant phenotype. No media change required. TILs continue expansion with IL-2 in presence of ASO. Re-dose after 3 to 5 days if sustained knockdown needed throughout pre-REP.
   Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)
   Note: Treating during pre-REP silences the target before the REP expansion, which is where the exhaustion program is driven hardest. Read the exhaustion markers at the end of REP against the untreated arm.
   Timing: Day 2-3 (re-dose after 3 to 5 days)
4. 04

   Step 4: Validation of knockdown

   At 48-72h post-ASO: extract RNA for qRT-PCR, expect 70-95% knockdown. At 72-96h: flow cytometry for surface checkpoint receptors (PD-1, LAG-3, TIM-3), measuring protein reduction as an MFI shift. Include a viability dye. Read the co-expression of the checkpoints, the PD-1+ TIM-3+ LAG-3+ triple-positive fraction, against the untreated arm.
   Materials: qRT-PCR reagents, flow cytometry antibodies (PD-1, LAG-3, TIM-3, CD8, CD4, viability dye)
   Note: Read the exhaustion markers, TIL viability and the activation markers (CD69, CD25) against the untreated arm.
   Timing: Day 4-6
5. 05

   Step 5: Tumor reactivity validation

   Critical: verify ASO treatment does not reduce tumor reactivity. Co-culture TILs with autologous tumor digest or tumor cell line (if available) at 1:1 E:T ratio for 4-18h. Measure IFN-γ production by ELISA or intracellular flow cytometry, degranulation (CD107a surface expression), tumor killing (flow-based viability of tumor targets), each against untreated TILs from the same batch.
   Materials: Autologous tumor digest or tumor cell line, IFN-γ ELISA, flow antibodies (CD107a, IFN-γ), tumor viability dyes
   Note: Gold standard validation: tumor-specific function, read against the untreated arm. Generic T cell activation (anti-CD3 beads) does not validate tumor reactivity.
   Timing: Day 7-10
6. 06

   Step 6: Proceed to REP

   After pre-REP completion (Day 10-14), transition to Rapid Expansion Protocol using checkpoint-reduced TILs as starting material. Standard REP protocol: harvest pre-REP TILs, count, seed at 1 × 10⁴-10⁵ cells/mL with 100-200 fold excess irradiated (50 Gy) allogeneic PBMCs (feeder cells), anti-CD3 (OKT3, 30 ng/mL), IL-2 (3000 U/mL), complete TIL medium. Expand 14-28 days (expect 1000-10,000 fold expansion).
   Materials: Irradiated feeder PBMCs, anti-CD3 (OKT3), IL-2
   Note: Read the REP performance of the checkpoint-knockdown arm against the untreated arm: fold-expansion during REP, and the memory phenotype at the end of it.
   Timing: Day 14 onward (REP phase)

Target exhaustion drivers during REP to improve expansion and phenotype

1. 01

   Step 1: Standard pre-REP completion

   Complete standard pre-REP expansion (7-14 days with IL-2). Harvest TILs, count, confirm viability >90%. Phenotype by flow cytometry: CD8/CD4 ratio, memory markers (CD62L, CCR7, CD45RO), exhaustion markers (PD-1, TIM-3, LAG-3) to establish baseline.
   Materials: Standard TIL medium + IL-2
   Note: Document baseline exhaustion state. TILs at pre-REP completion are already exhausted but about to undergo massive expansion stress (REP).
   Timing: Day 0-14 (pre-REP)
2. 02

   Step 2: REP initiation

   Standard REP setup: seed TILs at 1 × 10⁴-10⁵ cells/mL with 100-200 fold excess irradiated (50 Gy) allogeneic feeder PBMCs (healthy donor or pooled), anti-CD3 (OKT3, 30 ng/mL), IL-2 (3000 U/mL), complete TIL medium (10% human AB serum). Culture in T-flasks or gas-permeable bags. REP duration: 14-28 days depending on expansion kinetics.
   Materials: Irradiated feeder PBMCs, anti-CD3 (OKT3), IL-2 (3000 U/mL)
   Note: REP is aggressive expansion. Rapid proliferation (doubling every 24-48h) creates exhaustion pressure. Anti-CD3 + IL-2 drive activation but also exhaustion.
   Timing: REP Day 0
3. 03

   Step 3: AUMsilence sdASO treatment during REP (exhaustion prevention)

   At REP Day 7-10 (mid-expansion when exhaustion begins to accumulate), add AUMsilence sdASO targeting TOX (master exhaustion transcription factor) or NR4A1/2/3 (nuclear receptors driving exhaustion) at 10 μM. ASO is added directly to REP culture, no disruption to feeder cells or anti-CD3 stimulation. Re-dose every 3 to 5 days to maintain knockdown throughout rapid proliferation.
   Materials: AUMsilence sdASO anti-TOX or anti-NR4A1
   Note: TOX sits upstream of PD-1, TIM-3, LAG-3 and CD39, so one target covers what four checkpoint knockdowns would.
   Timing: REP Day 7-10 (re-dose every 3 to 5 days)
4. 04

   Step 4: REP monitoring and re-dosing

   Monitor TIL expansion: count cells every 2-3 days, expect 1000-5000 fold expansion over 14-21 days. When cell density exceeds 2-3 × 10⁶/mL, split culture or add fresh medium + IL-2. Each time medium refreshed or culture split, re-dose AUMsilence sdASO (10 μM final concentration). This maintains knockdown throughout REP despite rapid cell division diluting ASO.
   Materials: Fresh TIL medium + IL-2, AUMsilence sdASO for re-dosing
   Note: Rapid TIL division during REP (24-48h doubling time) dilutes ASO. Re-dosing every 3 to 5 days, at the short end of that interval while the cells are dividing this fast, compensates for dilution and maintains knockdown.
   Timing: REP Day 0-21
5. 05

   Step 5: REP completion and validation

   At REP Day 14-21 (when expansion plateaus or reaches target cell number, typically 10⁹-10¹¹ cells), harvest TILs. Validate: (1) Fold-expansion (count cells, calculate fold-increase from REP start), (2) Exhaustion marker expression: flow cytometry for PD-1, TIM-3, LAG-3, TOX, read against the untreated arm, (3) Memory phenotype: CD62L, CCR7, CD45RO, read against the untreated arm, because TOX drives the terminal differentiation that empties the central memory fraction, (4) Tumor reactivity: IFN-γ ELISPOT or co-culture with autologous tumor.
   Materials: Flow antibodies, IFN-γ ELISPOT reagents, autologous tumor cells
   Note: Fold-expansion, memory phenotype and tumor reactivity are the three readouts this protocol measures, each against the untreated arm of the same batch.
   Timing: REP Day 14-21
6. 06

   Step 6: Quality control

   Standard TIL QC: sterility testing (gram stain, culture), mycoplasma (PCR), viability (>70%), phenotype (CD3+, CD8/CD4 ratio), and tumor reactivity (IFN-γ ELISPOT vs. autologous tumor, criteria varies by institution/protocol). Cryopreserve or proceed to downstream assays.
   Materials: QC testing reagents, serum-free cryopreservation medium (10% DMSO)
   Note: The standard QC criteria apply unchanged to AUMsilence sdASO-treated TILs. Read viability and memory phenotype against the untreated arm.
   Timing: REP Day 21+

Combine activation-marker sorting with checkpoint knockdown to enrich and enhance tumor-reactive clones

1. 01

   Step 1: Pre-REP TIL stimulation with tumor antigens

   After initial TIL isolation and 2-3 day rest culture (IL-2 only), stimulate with autologous tumor digest (tumor cells from same patient) or tumor-derived peptide pools (if neoantigen sequences identified by whole-exome sequencing + HLA prediction algorithms). Co-culture TILs with tumor digest at 1:1 ratio for 18-24h. Tumor-reactive TILs upregulate activation markers: 4-1BB (CD137), OX40 (CD134), CD69, PD-1 (transiently increases).
   Materials: Autologous tumor digest or synthetic neoantigen peptides (20-mer, 10 μg/mL each), IL-2
   Note: Activation marker upregulation identifies neoantigen-specific TILs. 4-1BB (CD137) is gold standard marker; specifically upregulated on TCR-engaged T cells.
   Timing: Day 2-3 post-isolation
2. 02

   Step 2: Activation-marker sorting (4-1BB+ enrichment)

   At 18-24h post-tumor stimulation, harvest TILs and sort by flow cytometry or magnetic bead enrichment. Gate on live, CD3+CD8+ (or CD3+CD4+) cells. Sort 4-1BB+ (CD137+) population. This enriches for tumor-reactive TILs (typically 1-20% of total TILs, varies by tumor). 4-1BB+ cells are neoantigen-specific; 4-1BB- cells are bystander (non-reactive).
   Materials: Flow cytometry sorter or anti-CD137 magnetic beads, CD3, CD8, CD4, 4-1BB antibodies
   Note: Sorting enriches tumor reactivity 10-100 fold. 4-1BB+ sorted TILs show higher tumor killing, IFN-γ production, and clinical response correlation.
   Timing: Day 3-4
3. 03

   Step 3: AUMsilence sdASO enhancement of enriched TILs

   Immediately after sorting, culture 4-1BB+ enriched TILs in complete TIL medium + IL-2 (6000 U/mL). Add AUMsilence sdASO targeting checkpoint receptors (PD-1, LAG-3, TIM-3) or exhaustion drivers (TOX, NR4A1) at 10 μM. These neoantigen-specific TILs are highly exhausted (chronic tumor antigen exposure), and no cationic lipid or pulse is applied to a population this small.
   Materials: AUMsilence sdASO (PD-1, TOX, or combination)
   Note: This combines enrichment by sorting with knockdown. Read tumor reactivity of the sorted and treated population against the sorted population alone.
   Timing: Day 3-4
4. 04

   Step 4: Expansion of enhanced neoantigen-specific TILs

   Expand 4-1BB+ enriched + ASO-treated TILs using standard pre-REP (IL-2 only, 7-14 days) or proceed directly to REP (anti-CD3 + feeder cells + IL-2, 14-28 days). Re-dose AUMsilence sdASO every 3 to 5 days during expansion. Sorted populations expand more slowly than bulk TILs (smaller starting number, highly differentiated), but represent highest quality tumor-reactive cells.
   Materials: Standard pre-REP or REP reagents
   Note: Expansion of sorted TILs may yield lower total cell numbers but higher per-cell tumor reactivity. Quality vs. quantity tradeoff.
   Timing: Day 4-21
5. 05

   Step 5: Functional validation of neoantigen-specific TILs

   Validate tumor reactivity: (1) IFN-γ ELISPOT against autologous tumor, read against bulk TILs, (2) Tumor killing assays with autologous tumor cells at 1:1 E:T ratio, read against bulk TILs, (3) TCR sequencing: confirm clonal enrichment (TCRβ CDR3 sequences should show reduced diversity, high clonality of tumor-reactive clones), (4) Tetramer staining: if neoantigen HLA-peptide tetramers available, confirm enrichment of neoantigen-specific clones.
   Materials: IFN-γ ELISPOT, tumor cells, TCR sequencing, tetramers (optional)
   Note: This approach creates TIL populations enriched for tumor specificity, with few bystander cells, and it requires upfront tumor sequencing.
   Timing: Day 21+

Short-term checkpoint knockdown on TILs at the end of REP

1. 01

   Step 1: Post-REP TIL harvest

   Complete standard REP (14-28 days). Harvest TILs at Day 21-28 when expansion plateaus. Typical yield: 10⁹-10¹¹ cells depending on patient, tumor type, REP performance. Wash TILs 2× to remove feeder cells, anti-CD3, and excess cytokines. Resuspend in fresh TIL medium + IL-2 (reduced concentration, 1000 U/mL).
   Materials: Complete TIL medium + IL-2 (1000 U/mL)
   Note: Post-REP TILs are fully expanded but highly exhausted (PD-1, TIM-3, LAG-3 expression peaks at REP end), which is what a final knockdown is aimed at.
   Timing: REP Day 21-28
2. 02

   Step 2: Final AUMsilence sdASO treatment

   Add AUMsilence sdASO targeting checkpoint receptors (PD-1, LAG-3, TIM-3) or exhaustion/apoptosis genes (TOX, FAS) at 10 μM. Incubate 24-48h at 37°C to allow knockdown initiation. This short-term treatment is aimed at the checkpoint receptors at harvest, without requiring sustained knockdown (the cells are used within days).
   Materials: AUMsilence sdASO
   Note: Goal: knockdown that holds while the harvested cells are used. mRNA knockdown is typically achieved 24-72 hours after treatment.
   Timing: REP Day 21-23
3. 03

   Step 3: Quality control and validation

   After 24-48h ASO incubation, perform final QC: viability (>70%), sterility, phenotype (flow cytometry: CD3, CD8/CD4, checkpoint receptors; confirm knockdown initiated), tumor reactivity (IFN-γ ELISPOT rapid assay). If all QC pass, proceed to cryopreservation or to downstream assays.
   Materials: QC reagents, flow antibodies, IFN-γ ELISPOT
   Note: Checkpoint knockdown may not have reached its full protein reduction by harvest (only 24-48h elapsed) and continues afterwards. Early knockdown initiation sufficient.
   Timing: REP Day 23-25
4. 04

   Step 4: Cryopreservation

   For cryopreservation: resuspend TILs at 1-2 × 10⁸ cells/mL in serum-free cryopreservation medium (10% DMSO) or 90% FBS + 10% DMSO, freeze in controlled-rate freezer, transfer to vapor-phase liquid nitrogen.
   Materials: Cryopreservation medium, controlled-rate freezer
   Note: Read the knockdown after thaw, against the sample taken before freezing.
   Timing: REP Day 25+

Essential controls for TIL enhancement

• Untreated TILs (standard manufacturing): Baseline REP expansion, exhaustion markers, tumor reactivity
  Isolate, expand, and REP identically without ASO. Critical for reading what the treatment changes against standard manufacturing.
• Non-targeting control ASO: Control for ASO-related effects on TIL biology
  Use AUM non-targeting control at same concentration (10 μM) and timing. Verifies target specificity and rules out non-specific effects on REP or TIL function.
• Autologous tumor reactivity assay: Gold standard validation that ASO does not reduce tumor-specific function
  Critical: co-culture TILs with autologous tumor digest or tumor cell line. Measure IFN-γ, tumor killing and degranulation against untreated TILs. Generic anti-CD3 stimulation is not sufficient.
• Peripheral blood T cell comparison: Demonstrate TIL-specific biology vs. normal T cells
  Optional but valuable: treat peripheral blood T cells (from same patient or healthy donor) with same ASO protocol. TILs are more exhausted than peripheral T cells, which is what the comparison reads.

Optimization strategies for TIL applications

• Timing in manufacturing workflow
  Recommendation: Pre-REP (Day 2-3): checkpoint knockdown. REP mid-expansion (Day 7-10): exhaustion prevention (TOX, NR4A1). Post-REP (Day 21-23): final checkpoint knockdown.
  Rationale: The exhaustion program is driven hardest by the REP's rapid proliferation, so a pre-REP dose silences the target before that stress, a mid-REP dose holds the knockdown through it, and a post-REP dose acts on the harvested cells.
• ASO concentration
  Recommendation: The recommended working range is 5-20 μM, with a starting concentration of 10 μM. TILs are fragile; do not go above that range.
  Rationale: TILs are already stressed from tumor exposure and manufacturing. The starting concentration balances knockdown efficiency with minimal off-target risk, and dialing up is for when it shows inadequate knockdown.
• Duration and re-dosing during REP
  Recommendation: Re-dose every 3 to 5 days during REP, at the short end of that interval. TILs double every 24-48h during REP; ASO dilutes rapidly.
  Rationale: Rapid TIL proliferation during REP dilutes ASO. Re-dosing maintains knockdown throughout 14-28 day REP timeline. Single dose insufficient for sustained effect.
• Multi-target knockdown
  Recommendation: Can combine multiple ASOs: (1) Upstream exhaustion blockade: TOX alone (controls multiple checkpoints), (2) Multi-checkpoint knockdown: PD-1 + LAG-3 + TIM-3, (3) Exhaustion + tumor microenvironment resistance: TOX + TGFβR2. Keep the combined concentration within 5-20 μM.
  Rationale: TOX knockdown is efficient single target (upstream regulator). Multi-checkpoint knockdown blocks several receptors at once. Combination strategies address multiple failure modes.
• Treg depletion strategy
  Recommendation: FOXP3 knockdown at pre-REP (Day 2-3), in the contaminating Tregs, before REP expansion. Use 10 μM. Read the CD4+FOXP3+ percentage by flow against the untreated arm.
  Rationale: Tregs suppress effector TIL function. Silencing FOXP3 early acts before the REP expands the Treg fraction with everything else. FOXP3 knockdown is Treg-specific (CD4+CD8- effector T cells do not express FOXP3).
• Quality control integration
  Recommendation: Add knockdown validation to standard TIL QC: flow cytometry for target protein (PD-1, TOX, etc.) at REP completion. Compare ASO-treated vs. control side-by-side. Include in batch record documentation.
  Rationale: Validates manufacturing consistency batch-to-batch. Ensures ASO treatment achieving intended knockdown.

Troubleshooting

Validation reads whether the manufacturing keeps tumor reactivity. Gold standard: autologous tumor reactivity assays.

Quantitative RT-PCR (qRT-PCR) for mRNA knockdown

Protocol: Extract total RNA from TILs at 48-72h post-ASO treatment. Use phenol-guanidinium RNA extraction reagent or silica-membrane column RNA purification kit. Perform qRT-PCR with hydrolysis probe-based assays or SYBR Green primers. Normalize to housekeeping genes (GAPDH, ACTB, or B2M). Calculate fold-change using ΔΔCt method (compare ASO-treated vs. untreated TILs from same patient batch).

Expected Results: 70-95% knockdown, measured as mRNA reduction in TILs, for TOX, NR4A1 and the checkpoint receptors PD-1, LAG-3 and TIM-3.

Tips: TIL RNA quality variable (exhausted cells, tumor exposure); verify RNA integrity (RIN >7.0) before qPCR. For exhaustion markers (TOX, NR4A1), expression is induced during culture; knockdown prevents induction (compare to baseline Day 0 and untreated control). Include multiple housekeeping genes (GAPDH, ACTB, HPRT) to verify normalization stability.

Flow cytometry for protein knockdown and phenotyping

Protocol: At 72-96h post-ASO treatment (protein knockdown lags mRNA 24-48h), stain TILs for target protein and phenotypic markers. Surface staining: PD-1, LAG-3, TIM-3, CD39, CD8, CD4, CD62L, CCR7, CD45RO, CD45RA, 4-1BB, OX40. Include fixable viability dye (405 nm excitation). For intracellular proteins (TOX, NR4A1, FOXP3, IFN-γ, perforin, granzyme B): fix/permeabilize (transcription factor permeabilization buffer), stain with validated antibodies. Analyze on flow cytometer (8-10 color panel minimum). Gate: live singlets → CD3+ → CD8+ or CD4+ → assess target protein knockdown (MFI shift or percentage positive reduction).

Expected Results: protein reduction is read as a mean fluorescence intensity (MFI) shift. For a checkpoint target, read the MFI of that receptor and the PD-1+TIM-3+LAG-3+ triple-positive fraction against the untreated and the non-targeting control. Viability is read with the fixable viability dye in the same panel.

Tips: For exhaustion marker profiling, assess co-expression, not only individual markers (PD-1+ TIM-3+ double-positive or PD-1+ TIM-3+ LAG-3+ triple-positive identify severely exhausted cells, most responsive to intervention). For checkpoint receptors, MFI shift more sensitive than percentage positive (receptors have continuous expression). For TOX/NR4A1 (transcription factors), use validated intracellular antibodies; nuclear staining pattern expected. Compare to isotype controls or FMO (fluorescence minus one) for gating.

Tumor reactivity validation (IFN-γ ELISPOT)

Protocol: Co-culture TILs with autologous tumor digest (fresh or cryopreserved tumor cells from same patient) at 1:1 E:T ratio for 18-24h. Perform IFN-γ ELISPOT (enzyme-linked immunospot): (1) Coat ELISPOT plate with anti-IFN-γ capture antibody overnight, (2) Block, wash, (3) Add TILs + tumor digest (duplicate or triplicate wells, 10⁴-10⁵ TILs per well), (4) Incubate 18-24h, (5) Wash, add biotinylated anti-IFN-γ detection antibody, (6) Develop with streptavidin-HRP + AEC substrate, (7) Count spots (automated reader or manual). Include controls: TILs alone (no tumor), TILs + irrelevant target (HLA-mismatched cells), TILs + PMA/ionomycin (positive control, all T cells respond).

Expected Results: read the IFN-γ spot count of the treated TILs against untreated TILs from the same batch; that comparison is what says whether tumor reactivity was kept. An ELISPOT typically reads 50-500 spots per 10⁵ TILs, varying by patient, tumor type and tumor burden.

Tips: critical validation; if tumor reactivity is reduced, ASO has off-target effect on TCR signaling or TIL function. Troubleshoot (new ASO sequence, BLAST against TCR genes, validate with independent assay). Autologous tumor digest is gold standard (represents actual tumor antigens TILs encounter in vivo). If autologous tumor unavailable, use tumor cell line from same cancer type (less representative but informative). IFN-γ production correlates with tumor killing and clinical response.

Cytotoxicity assays (tumor killing)

Protocol: Co-culture TILs with tumor targets (autologous tumor digest, tumor cell lines, or patient-derived organoids) at multiple E:T ratios (10:1, 5:1, 1:1, 0.3:1). Measure target cell killing by: (1) Flow cytometry-based viability: label tumor targets with fluorescent cell tracking dye (such as succinimidyl ester-based proliferation dye or CFSE), co-culture 4-18h, stain with viability dye (7-AAD, propidium iodide), analyze labeled cells that are viability dye-positive (dead tumor cells) by flow. Calculate specific lysis: [(experimental death - spontaneous death) / (100 - spontaneous death)] × 100. (2) Impedance-based real-time killing: seed tumor cells in impedance monitoring system, add TILs, monitor impedance decrease (reflects tumor cell detachment/death) over 24-48h. (3) Luciferase-expressing tumor targets: co-culture, measure luminescence reduction (dead tumor cells lose luciferase signal).

Expected Results: read specific lysis at the lower E:T ratios (1:1, 3:1) against untreated TILs from the same batch, which is also the ratio a TIL meets in a tumor. At the high ratios (10:1, 20:1) a ceiling effect hides any difference, which is why the low ones are the ones to read. Serial rechallenge, harvesting TILs after 48h onto fresh tumor targets, reads how long killing is sustained.

Tips: use low E:T ratios (1:1, 0.3:1), which are also the ratios a TIL meets in a tumor, where it is outnumbered. Autologous tumor targets gold standard. Serial rechallenge assays test TIL persistence and exhaustion: read how many rounds of killing each arm sustains. For REP-expanded TILs (large cell numbers), can test multiple tumor targets, E:T ratios, timepoints in parallel.

REP expansion kinetics and fold-expansion calculation

Protocol: During REP (Days 0-21), count TILs every 2-3 days using automated cell counter (Cellometer, Vi-CELL) or manual hemocytometer. Calculate: (1) Absolute cell number each timepoint, (2) Population doublings: log₂(final cell number / initial cell number), (3) Fold-expansion: final cell number / initial cell number. Compare ASO-treated vs. untreated TILs from same patient batch. Plot growth curves (cell number vs. time, log scale). Calculate doubling time.

Expected Results: a standard TIL REP expands 1000-5000 fold over 14-21 days, 8-12 population doublings, at a doubling time of 30-48h. Read the fold-expansion of the treated arm against the untreated arm of the same patient batch, which is the comparison a low-responding batch turns on.

Tips: Fold-expansion is manufacturing-critical endpoint; directly impacts clinical dose (target 10⁹-10¹¹ cells). An improvement in fold-expansion can rescue a failing batch. Compare within-patient (same TIL batch split: ASO-treated vs. untreated); eliminates patient-to-patient variability. Monitor cell viability during REP (should remain >90%); expansion failure often due to cell death not proliferation defect. For multi-patient studies, normalize to baseline (fold-change vs. untreated control for each patient) to account for variability.

Memory and differentiation marker profiling

Protocol: At REP completion (Day 21), stain TILs for memory and differentiation markers. Naive: CD45RA+CD62L+CCR7+ (rare in TILs). Central memory (CM): CD45RO+CD62L+CCR7+ (best persistence). Effector memory (EM): CD45RO+CD62L-CCR7- (immediate killing, poor persistence). Terminally differentiated effectors (TEMRA): CD45RA+CD62L-CCR7-CD27-CD28- (senescent). Also include: CD127 (IL-7Rα, memory marker), KLRG1 (senescence marker), Ki67 (proliferation marker). Analyze by flow cytometry: gate live CD3+CD8+ (or CD4+), quantify subset percentages.

Expected Results: a standard REP ends with central memory depleted (CM 5-15%) and effector memory and TEMRA accumulated (70-90%). TOX drives the exhaustion program, so read the CM fraction and the KLRG1+ senescent fraction of the treated arm against the untreated arm. A higher central memory fraction is the phenotype the TIL literature associates with in vivo persistence.

Tips: Memory phenotype is a quality metric (not quantity). High-quality TIL product has balanced memory-effector distribution (optimal: 10-30% CM, 50-70% EM, <20% TEMRA). All-effector products (common in standard REP) provide immediate killing but poor persistence (patient relapses within months). CM-enriched products provide durability. TOX and NR4A1 drive terminal differentiation, so the CM fraction is the readout where they are the target. Include at pre-REP baseline (Day 0) to assess phenotypic drift during REP.

TCR sequencing for clonal diversity and repertoire analysis

Protocol: Extract genomic DNA or RNA from TILs at pre-REP (Day 0) and REP completion (Day 21). Perform TCRβ CDR3 sequencing (a commercial immune repertoire sequencing service or in-house protocol). Analyze: (1) Clonal diversity: Shannon entropy, Simpson index (higher = more diverse), (2) Top clone frequency: percentage of most abundant clone (clonal dominance), (3) Repertoire overlap: Morisita index comparing pre-REP vs. post-REP (measures repertoire stability), (4) Tracking: identify top 10-20 clones at pre-REP, track their frequencies post-REP (do tumor-reactive clones persist or get outcompeted?). If neoantigen-specific clones known (from tetramer staining or functional assays), track their frequencies specifically.

Expected Results: a standard REP often reduces diversity (clonal contraction: Shannon entropy falls, the top clone's frequency rises from 5-10% pre-REP to 20-40% post-REP), and some tumor-reactive clones may be lost (<1% post-REP). Read the treated arm's entropy, its repertoire overlap with the pre-REP sample and the frequency of its tumor-reactive clones against the untreated arm.

Tips: TCR sequencing is expensive but highly informative. Reveals clonal-level ASO effects invisible to bulk assays. If specific tumor-reactive clones identified (e.g., by tetramer sorting or single-cell TCR+RNA-seq), their maintenance post-REP is strongest predictor of clinical response. Diversity is proxy for multi-antigen tumor coverage; diverse TILs less vulnerable to antigen escape. Can correlate TCR repertoire features with clinical outcomes (if patient samples available).

In vivo tumor models

Protocol: Establish patient-derived xenograft (PDX) tumors in immunodeficient mice: implant tumor fragments subcutaneously or orthotopically, allow growth to 100-200 mm³. Humanize mice (optional): inject human PBMCs or CD34+ HSCs to provide immune context. Treat mice: lymphodepleting chemotherapy (cyclophosphamide + fludarabine, Days -5 to -2), TIL infusion (IV or intratumoral, 1-5 × 10⁶ cells, Day 0), human IL-2 support (IP, 30,000-60,000 U, Days 0-4). Monitor: tumor size (caliper measurements, 2-3× per week), survival (Kaplan-Meier), TIL persistence in blood/tumor (collect blood weekly, harvest tumor at endpoint, stain for human CD3, CD8, CD4, CD45, analyze by flow cytometry). Compare: untreated TILs, checkpoint-knockout TILs, exhaustion-reversed TILs, no TIL control.

Expected Results: read tumor volume, survival, and human CD3+ cells in blood and tumor at Days 7, 14 and 21, each against the arm given untreated TILs from the same batch. At endpoint, harvest the tumor and stain the tumor-infiltrating TILs for PD-1, TIM-3 and TOX against that arm.

Tips: In vivo validation is the gold standard but resource-intensive (expensive, long timeline 2-4 months). Prioritize after in vitro validation (knockdown, tumor reactivity, REP expansion). PDX models most relevant (patient tumor tissue) but require fresh tumor specimens and engraftment time (4-8 weeks). Alternative: established tumor cell lines (faster but less clinically relevant). Human IL-2 required for TIL survival in mice (mouse IL-2 does not fully support human TILs). Correlate in vivo efficacy with in vitro features (memory phenotype, tumor reactivity, exhaustion markers); identify predictive biomarkers.

Critical controls for TIL validation

• Untreated TILs (standard manufacturing)
  Purpose: Baseline for all comparisons
  Isolate from same tumor specimen, culture identically (same IL-2, same REP protocol, same timing) without ASO. This is the gold standard control; any enhancement must be demonstrated vs. untreated TILs from same patient.
• Non-targeting control ASO
  Purpose: Control for non-specific ASO effects
  Use AUM non-targeting control at 10 μM, same timing as experimental ASO. Verifies target specificity and rules out ASO-related effects on TIL biology (innate immune activation, off-target binding, etc.).
• Autologous tumor reactivity (every experiment)
  Purpose: Essential functional validation; reads whether tumor-specific function is kept
  Critical: include IFN-γ ELISPOT or cytotoxicity assay vs. autologous tumor in every TIL enhancement experiment. This is non-negotiable in any TIL study: confirm the ASO does not reduce tumor reactivity. Generic anti-CD3 stimulation is not sufficient.
• Peripheral blood T cell comparison (optional)
  Purpose: Demonstrate TIL-specific biology
  Optional but valuable: treat healthy peripheral blood T cells (from patient or healthy donor) with same ASO protocol. TILs are more exhausted than peripheral T cells, which is what the comparison reads.
• Dose-response and sequence verification
  Purpose: Confirm on-target effects and optimal concentration
  Test ASO dose-response (5 μM, 10 μM and 20 μM); knockdown should be concentration-dependent. Design 3-5 independent ASO sequences targeting different regions of same gene; concordant phenotypes confirm on-target effects and rule out sequence-specific artifacts.

Best practices

• Use patient-matched controls (untreated TILs from same tumor specimen); eliminates patient variability
• Validate knockdown at both mRNA (qRT-PCR, 48h) and protein (flow, 72-96h) levels
• Always include autologous tumor reactivity assay (IFN-γ ELISPOT or cytotoxicity); gold standard functional validation
• Monitor TIL viability throughout manufacturing
• For REP expansion studies, calculate fold-expansion and population doublings (normalized metrics)
• Report exhaustion marker co-expression (PD-1+TIM-3+LAG-3+ triple-positive), not only individual markers
• Include memory phenotype profiling (CD62L, CCR7); predicts in vivo persistence potential
• Use biological replicates (n≥3 patient TIL batches minimum for statistical power)
• Document baseline tumor characteristics (tumor type, stage, prior treatments); influences TIL biology
• Compare results to literature benchmarks (standard TIL REP: 1000-5000 fold expansion)